Article Text

PDF
Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed
  1. Lavnish Joshi1,2,
  2. Satish Yaganti1,
  3. Maria Gemenetzi1,
  4. Sue Lightman1,2,
  5. Dan Lindfield1,
  6. Vasilis Liolios1,
  7. Victor Menezo1,3,
  8. Emily Shao1,
  9. Simon R J Taylor1,4
  1. 1Department of Ophthalmology, Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK
  2. 2UCL Institute of Ophthalmology, London, UK
  3. 3Department of Ophthalmology, Institut Catala de Retina, Barcelona, Spain
  4. 4Faculty of Medicine, Imperial College London, London, UK
  1. Correspondence to Dr Simon R J Taylor, Faculty of Medicine, Imperial College London, 5N8B Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK; s.r.taylor{at}imperial.ac.uk

Abstract

Objective To report the 12-month outcomes of the dexamethasone intravitreal implant in retinal vein occlusion (RVO), using an as-needed repeat injection protocol.

Design Retrospective consecutive case series of 51 eyes of 49 patients with macular oedema as a result of RVO that received an intravitreal dexamethasone implant and were followed up for at least 12 months.

Results 70% of patients responded to dexamethasone implant injection with an improvement in visual acuity (VA) and macular oedema within 3 months of injection, but only 30% of eyes gained ≥15 letters. The mean change in VA letter score at 12 months compared with baseline for branch RVO (BRVO) and central RVO (CRVO) was 5.7±2.3 and 11.5±11.0 EDTRS letters, respectively. 56% of patients relapsed, with the median time to relapse being 17 weeks for patients with branch RVO and 18 weeks for patients with CRVO. Repeat injections achieved similar VA gains, but the duration of effect of repeat dexamethasone implants was much shorter at 10 weeks. 14 eyes (27%) developed a significant rise in intraocular pressure, and three of these required treatment with oral acetazolamide. Four eyes with CRVO developed neovascular glaucoma during the study.

Conclusions The intravitreal dexamethasone implant does not last the 6 months implied by the retreatment protocol in the GENEVA trial, and improved results can be achieved with an as-needed retreatment protocol, particularly in CRVO. However, visual outcomes remain similar to those previously seen with triamcinolone in the SCORE study and neovascular complications remain a feature of CRVO.

  • Retina
  • Treatment Medical

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.